| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 450 | 2020 |
| Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) F Bigot, E Castanon, C Baldini, A Hollebecque, A Carmona, ... European Journal of Cancer 84, 212-218, 2017 | 163 | 2017 |
| What every oncologist should know about geriatric assessment for older patients with cancer: young international society of geriatric oncology position paper KP Loh, E Soto-Perez-de-Celis, T Hsu, NA de Glas, NML Battisti, ... Journal of oncology practice 14 (2), 85-94, 2018 | 152 | 2018 |
| Long-term survival in patients responding to anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation ML Gauci, E Lanoy, S Champiat, C Caramella, S Ammari, S Aspeslagh, ... Clinical Cancer Research 25 (3), 946-956, 2019 | 125 | 2019 |
| Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study G Manson, ATJ Maria, F Poizeau, FX Danlos, M Kostine, S Brosseau, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 80 | 2019 |
| Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations AR Mislang, TM Wildes, R Kanesvaran, C Baldini, HM Holmes, ... Cancer treatment reviews 57, 58-66, 2017 | 72 | 2017 |
| Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed … A Bernard-Tessier, C Baldini, P Martin, S Champiat, A Hollebecque, ... European Journal of Cancer 101, 160-164, 2018 | 61 | 2018 |
| Impact of aging on immune-related adverse events generated by anti–programmed death (ligand) PD-(L) 1 therapies C Baldini, PM Romano, AL Voisin, FX Danlos, S Champiat, S Laghouati, ... European Journal of Cancer 129, 71-79, 2020 | 59 | 2020 |
| Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients A Mailliez, C Baldini, JT Van, V Servent, Y Mallet, J Bonneterre British journal of cancer 103 (6), 772-775, 2010 | 59 | 2010 |
| The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry V Ruste, V Goldschmidt, A Laparra, S Messayke, FX Danlos, ... European Journal of Cancer 158, 217-224, 2021 | 44 | 2021 |
| Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1 JM Michot, M Fusellier, S Champiat, C Velter, C Baldini, AL Voisin, ... Annals of the rheumatic diseases 78 (7), e67-e67, 2019 | 44 | 2019 |
| The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study JM Michot, A Lappara, J Le Pavec, A Simonaggio, M Collins, E De Martin, ... European Journal of Cancer 130, 39-50, 2020 | 43 | 2020 |
| Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis C Baldini, A Escande, O Bouché, F El Hajbi, J Volet, V Bourgeois, ... Pancreatology 17 (1), 146-149, 2017 | 35 | 2017 |
| Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors) R Sun, S Champiat, L Dercle, S Aspeslagh, E Castanon, EJ Limkin, ... European Journal of Cancer 84, 202-211, 2017 | 34 | 2017 |
| First-in-human phase I study of a next-generation, oral, TGFβ receptor 1 inhibitor, LY3200882, in patients with advanced cancer TA Yap, M Vieito, C Baldini, JM Sepúlveda-Sánchez, S Kondo, ... Clinical Cancer Research 27 (24), 6666-6676, 2021 | 33 | 2021 |
| Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours H Herin, S Aspeslagh, E Castanon, V Dyevre, A Marabelle, A Varga, ... European Journal of Cancer 95, 68-74, 2018 | 31 | 2018 |
| Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis N de’Angelis, C Baldini, R Brustia, P Pessaux, D Sommacale, A Laurent, ... PLoS One 15 (4), e0230914, 2020 | 29 | 2020 |
| VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments T Payen, A Dizeux, C Baldini, D Le Guillou-Buffello, M Lamuraglia, ... Ultrasound in medicine & biology 41 (8), 2202-2211, 2015 | 28 | 2015 |
| Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types P Martin‐Romano, E Castanon, S Ammari, S Champiat, A Hollebecque, ... Cancer medicine 9 (8), 2643-2652, 2020 | 27 | 2020 |
| PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper G Liposits, KP Loh, E Soto-Perez-de-Celis, L Dumas, NML Battisti, ... Journal of geriatric oncology 10 (2), 337-345, 2019 | 25 | 2019 |
